Epiroc AB (publ)
EPIAF News Today: Stay Updated with the Latest Epiroc AB (publ) News in Real Time
Find EPIAF news now at Meyka AI. Stay informed with the latest Epiroc AB (publ) stocks updates, including price news, market analysis, and expert insights.
ERCB.DE Stock Rises 0.1% as Ericsson Prepares April 17 Earnings
ERCB.DE stock at €10.2 on XETRA. Telefonaktiebolaget LM Ericsson earnings announcement April 17. Meyka AI rates B+.
EQBBF Downgraded to Neutral from Buy at Citigroup April 2026
Citigroup downgraded EQBBF from Buy to Neutral on April 13, 2026, signaling reduced confidence in EQT AB (publ).
SVNLY Analyst Rating Maintained at Hold by Deutsche Bank April 2026
Deutsche Bank maintains Hold rating on SVNLY, raises price target to SEK 135 on April 13, 2026.
SVKEF Analyst Rating Maintained at Hold by Deutsche Bank April 2026
Deutsche Bank maintains Hold rating on SVKEF, raises price target to SEK 190 on April 13, 2026.
SSAAY Maintained at Hold by Deutsche Bank April 2026
Deutsche Bank maintains SSAAY at Hold with price target raised to SEK 72 on April 13, 2026
HXGBY Maintained at Hold by Deutsche Bank, April 2026
Deutsche Bank maintains Hold rating on HXGBY, lowers price target to SEK 100 from SEK 110 on April 13, 2026.
XVIPY Xvivo Perfusion PNK $6.54 08 Apr 2026: Oversold bounce may reach $9.58
XVIPY stock update: $6.54, oversold-bounce setup with Meyka AI forecast to $9.58 and 46.48% upside
XVIPY (Xvivo Perfusion AB PNK) 17 Mar 2026: Oversold bounce at $6.54
XVIPY stock at **$6.54** on 17 Mar 2026. Short-term oversold bounce setup with Meyka AI forecast of **$9.58**
XVIPY $6.54 Xvivo Perfusion AB (PNK) 13 Mar 2026: oversold bounce, watch $8.00 target
XVIPY stock at $6.54 shows an oversold bounce on 13 Mar 2026; Meyka AI forecast 1-year $9.58, implied upside 46.48%